Dey H M, Karimeddini M K, Spencer R P, Sziklas J J
J Nucl Med. 1985 Nov;26(11):1270-4.
The kidneys were evaluated on [99mTc]phosphonate bone scans using 35 studies from 23 individuals with multiple myeloma; these images were compared with those from 50 controls. In each case, the kidneys could be visualized and calculation was made of the renal:skeleton ratio. Two myeloma patients showed an elevated renal:skeleton ratio. One was due to reduced vertebral uptake of [99mTc]phosphonate following therapeutic radiation. In the second case, the elevated ratio was related to renal uptake of the tracer (independent of urinary retention), and was consistent with nephrocalcinosis. No significant correlation between the renal:skeleton ratio and the degree of hypercalcemia, proteinuria, or renal impairment was found. We conclude that bone scintigraphy represents a safe, simple means of demonstrating renal presence and activity in multiple myeloma patients. However, calculation of the renal:skeleton ratio is not directly helpful in clarifying the events of calcium metabolism.
利用23例多发性骨髓瘤患者的35项研究,通过[99mTc]膦酸盐骨扫描对肾脏进行评估;将这些图像与50名对照者的图像进行比较。在每种情况下,肾脏均可显影,并计算肾骨比。两名骨髓瘤患者的肾骨比升高。其中一例是由于治疗性放疗后椎体对[99mTc]膦酸盐的摄取减少。在第二例中,该比值升高与示踪剂的肾脏摄取有关(与尿潴留无关),且与肾钙质沉着症一致。未发现肾骨比与高钙血症程度、蛋白尿或肾功能损害之间存在显著相关性。我们得出结论,骨闪烁显像术是一种显示多发性骨髓瘤患者肾脏存在及活性的安全、简便方法。然而,计算肾骨比对于阐明钙代谢情况并无直接帮助。